The international St-aging system as a prognostic marker in general senior population: Findings from the EPIDOS cohort study.
The international St-aging system as a prognostic marker in general senior population: Findings from the EPIDOS cohort study. Eur J Intern Med. 2019 Aug 03;: Authors: Pouzoullic M, Schott AM, Sánchez-Rodríguez D, Bataille R, Annweiler C, SOCOS group Abstract The International Staging System (ISS) -calculated from serum albumin and beta-2 microglobulin (β2m)- is an established prognostic marker in multiple myeloma (MM), which has also been suggested to account for survival among general senior population. Our objective was to examine long-term survival of older women free of MM according to baseline ISS. The study included 230 community-dwelling healthy older women without known MM from the EPIDOS cohort (mean ± SD, 80.4 ± 3.4 years). Serum albumin and β2m were measured at baseline, and used to calculate the ISS a posteriori. Abnormal ISS was defined as ISS = 2 or ISS = 3, although ISS = 1 was considered normal. The vital status was sought after a mean follow-up of 17.6 ± 0.2 years (range, 16.8-18.3). Age, body mass index, mean arterial pressure, diabetes mellitus, hypertension, coronary heart disease, stroke, use corticosteroids, number of drugs daily taken, smoking, physical activity, fall history, bone mineral density, and creatinine clearance were used as potential confounders. All participants died during the 17-year follow-up. Compared to women with normal ISS, those with abnor...
' There's once again excitement about renal artery denervation and … it's justified,'says one cardiologist, while another hopes for FDA approval next year, and a third is'still not 100% convinced. 'theheart.org on Medscape
Conditions: Advanced Solid Tumors; B Cell Lymphoma; Multiple Myeloma Intervention: Drug: DeltaRex-G Sponsor: Aveni Foundation Temporarily not available
Condition: Multiple Myeloma Interventions: Drug: Belantamab mafodotin; Drug: Bortezomib; Drug: Lenalidomide; Drug: Dexamethasone Sponsor: GlaxoSmithKline Not yet recruiting
Conditions: Pulmonary Arterial Hypertension; Right-Sided Heart Failure Intervention: Other: PET/MRI Sponsors: University of Wisconsin, Madison; United Therapeutics Recruiting
Conditions: Advanced Malignant Solid Neoplasm; Caregiver; Metastatic Malignant Solid Neoplasm; Recurrent Leukemia; Recurrent Lymphoma; Recurrent Malignant Solid Neoplasm; Recurrent Plasma Cell Myeloma Intervention: Other: Questionnaire Administration Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI) Not yet recruiting
Condition: Type 2 Diabetes Intervention: Diagnostic Test: Continuous glucose monitoring Sponsors: Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran; AztraZeneca Recruiting
Conditions: Pregnancy; Gestational Diabetes Intervention: Behavioral: TLC Group Prenatal Care Sponsor: Washington University School of Medicine Not yet recruiting
Condition: Diabetes Mellitus, Type 2 Intervention: Device: BD Diabetes Care Application (for mobile devices) PLUS use of BD Nano Pen Needle Sponsor: Becton, Dickinson and Company Recruiting
Condition: Diabetic Foot Interventions: Drug: PRP gel; Drug: Saline dressing Sponsor: Mansoura University Completed
Treating a loved one who is having an episode of severe hypoglycemia can be a frightening experience. Dr Anne Peters discusses the promising use of recently approved nasal glucagon.Medscape Diabetes &Endocrinology